Skip to main content

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708456/Champions-Oncology-to-Announce-Fourth-Quarter-Financial-Results-on-Thursday-July-21-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.48
+1.72 (0.76%)
AAPL  271.36
-0.83 (-0.30%)
AMD  214.59
+13.53 (6.73%)
BAC  55.23
+0.97 (1.79%)
GOOG  305.89
+2.14 (0.71%)
META  665.66
+1.21 (0.18%)
MSFT  483.62
-0.37 (-0.08%)
NVDA  180.92
+6.78 (3.89%)
ORCL  193.52
+13.49 (7.49%)
TSLA  482.30
-1.07 (-0.22%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.